Cai Hong-Qiao, Zhang Li-Yue, Fu Li-Ming, Xu Bin, Jiao Yan
Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun 130021, Jilin Province, China.
Department of Critical Care Medicine, The First Hospital of Jilin University, Changchun 130021, Jilin Province, China.
World J Gastrointest Surg. 2024 Feb 27;16(2):276-283. doi: 10.4240/wjgs.v16.i2.276.
In this editorial we comment on an article published in a recent issue of the . A common gene mutation in gastric cancer (GC) is the TP53 mutation. As a tumor suppressor gene, TP53 is implicated in more than half of all tumor occurrences. TP53 gene mutations in GC tissue may be related with clinical pathological aspects. The TP53 mutation arose late in the progression of GC and aided in the final switch to malignancy. CDH1 encodes E-cadherin, which is involved in cell-to-cell adhesion, epithelial structure maintenance, cell polarity, differentiation, and intracellular signaling pathway modulation. CDH1 mutations and functional loss can result in diffuse GC, and CDH1 mutations can serve as independent prognostic indicators for poor prognosis. GC patients can benefit from genetic counseling and testing for CDH1 mutations. Demethylation therapy may assist to postpone the onset and progression of GC. The investigation of TP53 and CDH1 gene mutations in GC allows for the investigation of the relationship between these two gene mutations, as well as providing some basis for evaluating the prognosis of GC patients.
在这篇社论中，我们对近期一期《 》上发表的一篇文章进行评论。胃癌（GC）中常见的基因突变是TP53突变。作为一种肿瘤抑制基因，TP53参与了超过一半的肿瘤发生。GC组织中的TP53基因突变可能与临床病理特征有关。TP53突变在GC进展后期出现，并促成了最终向恶性肿瘤的转变。CDH1编码E-钙黏蛋白，其参与细胞间黏附、上皮结构维持、细胞极性、分化以及细胞内信号通路调节。CDH1突变和功能丧失可导致弥漫性GC，且CDH1突变可作为预后不良的独立预后指标。GC患者可从CDH1突变的遗传咨询和检测中获益。去甲基化疗法可能有助于延缓GC的发生和进展。对GC中TP53和CDH1基因突变的研究有助于探究这两种基因突变之间的关系，并为评估GC患者的预后提供一些依据。
